These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 39163145)

  • 1. Evaluation of a Benzodiazepine Immunoassay for Urine Drug Testing in Clinical Specimens.
    Ge M; Alabi A; Kelner MJ; Fitzgerald RL; Suhandynata RT
    J Appl Lab Med; 2024 Nov; 9(6):964-976. PubMed ID: 39163145
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of two highly sensitive benzodiazepine immunoassay lab developed tests for urine drug testing in clinical specimens.
    Lund K; Menlyadiev M; Lee K; Kelner MJ; Fitzgerald RL; Suhandynata RT
    J Mass Spectrom Adv Clin Lab; 2023 Apr; 28():91-98. PubMed ID: 36937812
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Urine benzodiazepine screening using Roche Online KIMS immunoassay with beta-glucuronidase hydrolysis and confirmation by gas chromatography- mass spectrometry.
    Klette KL; Wiegand RF; Horn CK; Stout PR; Magluilo J
    J Anal Toxicol; 2005 Apr; 29(3):193-200. PubMed ID: 15842763
    [TBL] [Abstract][Full Text] [Related]  

  • 4. KIMS, CEDIA, and HS-CEDIA immunoassays are inadequately sensitive for detection of benzodiazepines in urine from patients treated for chronic pain.
    Darragh A; Snyder ML; Ptolemy AS; Melanson S
    Pain Physician; 2014; 17(4):359-66. PubMed ID: 25054395
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Limitations of EMIT benzodiazepine immunoassay for monitoring compliance of patients with benzodiazepine therapy even after hydrolyzing glucuronide metabolites in urine to increase cross-reactivity: comparison of immunoassay results with LC-MS/MS values.
    Dixon RB; Floyd D; Dasgupta A
    Ther Drug Monit; 2015 Feb; 37(1):137-9. PubMed ID: 25004136
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Urine Drug Screening in the Era of Designer Benzodiazepines: Comparison of Three Immunoassay Platforms, LC-QTOF-MS and LC-MS-MS.
    Puzyrenko A; Wang D; Schneider R; Wallace G; Schreiber S; Brandt K; Gunsolus IL
    J Anal Toxicol; 2022 Aug; 46(7):712-718. PubMed ID: 34557900
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of Two Immunoassay Screening Methods and a LC-MS/MS in Detecting Traditional and Designer Benzodiazepines in Urine.
    Rossi B; Freni F; Vignali C; Stramesi C; Collo G; Carelli C; Moretti M; Galatone D; Morini L
    Molecules; 2021 Dec; 27(1):. PubMed ID: 35011344
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detectability of designer benzodiazepines in CEDIA, EMIT II Plus, HEIA, and KIMS II immunochemical screening assays.
    Pettersson Bergstrand M; Helander A; Hansson T; Beck O
    Drug Test Anal; 2017 Apr; 9(4):640-645. PubMed ID: 27366870
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oxaprozin cross-reactivity in three commercial immunoassays for benzodiazepines in urine.
    Fraser AD; Howell P
    J Anal Toxicol; 1998; 22(1):50-4. PubMed ID: 9491969
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative evaluation of the accuracy of benzodiazepine testing in chronic pain patients utilizing immunoassay with liquid chromatography tandem mass spectrometry (LC/MS/MS) of urine drug testing.
    Manchikanti L; Malla Y; Wargo BW; Fellows B
    Pain Physician; 2011; 14(3):259-70. PubMed ID: 21587329
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of urinary benzodiazepines and their metabolites: comparison of automated HPLC and GC-MS after immunoassay screening of clinical specimens.
    Valentine JL; Middleton R; Sparks C
    J Anal Toxicol; 1996 Oct; 20(6):416-24. PubMed ID: 8889678
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New fluorescence polarization immunoassays for analysis of barbiturates and benzodiazepines in serum and urine: performance characteristics.
    Schwenzer KS; Pearlman R; Tsilimidos M; Salamone SJ; Cannon RC; Wong SH; Gock SB; Jentzen JJ
    J Anal Toxicol; 2000; 24(8):726-32. PubMed ID: 11110029
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Measurement of benzodiazepines in urine by liquid chromatography-tandem mass spectrometry: confirmation of samples screened by immunoassay.
    Glover SJ; Allen KR
    Ann Clin Biochem; 2010 Mar; 47(Pt 2):111-7. PubMed ID: 19969595
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic monitoring of benzodiazepines in the management of pain: current limitations of point of care immunoassays suggest testing by mass spectrometry to assure accuracy and improve patient safety.
    Mikel C; Pesce AJ; Rosenthal M; West C
    Clin Chim Acta; 2012 Aug; 413(15-16):1199-202. PubMed ID: 22484396
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CEDIA dau Benzodiazepine screening assay: a reformulation.
    Meatherall RC; Fraser AD
    J Anal Toxicol; 1998; 22(4):270-3. PubMed ID: 9681328
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of immunoassay screening tests and LC-MS-MS for urine detection of benzodiazepines and their metabolites: results of a national proficiency test.
    Bertol E; Vaiano F; Borsotti M; Quercioli M; Mari F
    J Anal Toxicol; 2013; 37(9):659-64. PubMed ID: 23943436
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Comparative Analysis of Two Commonly Used FDA-Approved Immunoassays for Fentanyl Detection.
    Lam KHB; Menlyadiev M; Buggs V; Parnprome S; Pesce A; Suhandynata RT; Fitzgerald RL; Song L; Metushi IG
    J Appl Lab Med; 2024 Sep; 9(5):905-912. PubMed ID: 38831664
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Despite the improved clinical sensitivity of the Roche benzodiazepines II assay it cannot replace mass spectrometry in all patient populations.
    Tolan NV; Uljon S; Lauren Donnelly-Morell M; Zhao M; Mahowald GK; Snyder ML; Contella L; Urwiller ED; Daluz Fernandes M; Kang P; Melanson SEF
    J Mass Spectrom Adv Clin Lab; 2024 Aug; 33():14-20. PubMed ID: 39041051
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of urine and oral fluid as matrices for screening of thirty-three benzodiazepines and benzodiazepine-like substances using immunoassay and LC-MS(-MS).
    Smink BE; Mathijssen MP; Lusthof KJ; de Gier JJ; Egberts AC; Uges DR
    J Anal Toxicol; 2006 Sep; 30(7):478-85. PubMed ID: 16959142
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Benzodiazepine screening using EMIT II and TDx: urine hydrolysis pretreatment required.
    Meatherall R
    J Anal Toxicol; 1994; 18(7):385-90. PubMed ID: 7861751
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.